AI-Based Clinical Trial Solutions for Patient Matching Market Report 2022: Growing Government Activities to Encourage the Use of Artificial Intelligence (AI) Drives Sector –

Dublin–(business wire)–“AI-Based Clinical Trial Solutions for Patient Matching Market By Therapeutic Application, By End-User, By Region – Global Forecast 2023-2033” report has been added. of Recruitment.

The market size of AI-based clinical trial solutions is estimated at USD 235.21 million in 2022 and is expected to grow at a CAGR of 27.21% during the forecast period of 2023-2033. Adoption of AI-powered solutions in the management and conduct of clinical trials; growing government action to promote the use of artificial intelligence (AI) technologies in the healthcare industry; rising healthcare spending by major players; The growing public awareness is that: It is projected to drive the market growth in the near future. However, issues related to data privacy are projected to limit market growth.

Increasing governmental activities to encourage the use of artificial intelligence (AI) technologies in the healthcare industry is expected to boost the market growth. Government agencies in developed countries such as the US and Europe are funding the development of AI-based clinical trial research solutions while establishing strict regulatory frameworks.

Additionally, developing country governments are training stakeholders on AI-based clinical trial solutions so they can focus on discovering new treatments and accelerating patient enrollment, resulting in better patient engagement and monitoring. .

Increasing healthcare spending by major players is projected to drive the market growth. In developed countries, healthcare IT spending accounts for a significant portion of healthcare costs. Countries are adopting AI-based solutions to reduce costs and improve productivity. For example, in September 2022, the National Institutes of Health (NIH) launched his Bridge2AI project. It includes participants from many organizations and focuses on developing a variety of tools, resources, and data for developing AI strategies.


By therapeutic use

The market is segmented into cardiovascular diseases, infectious diseases, metabolic diseases, oncology, neurological diseases, and others. In 2022, the oncology segment accounted for the highest revenue share due to the rising prevalence of cancer worldwide. A large pharmaceutical company is working with an AI developer to deploy an AI-based oncology technology designed for drug development.

By end user

The market is segmented into academia, pharmaceutical companies, and others. As the global market increasingly focuses on the development of biomarkers and diagnostics, pharmaceutical companies in this segment accounted for the largest revenue share in 2022. For example, IQVIA’s text mining system Linguamatics offers his NLP-based solution for pharmaceutical companies. The pharmaceutical industry is expanding as a result of rising prevalence of chronic diseases and increasing demand for customized treatments.

The market is also benefiting from partnerships with major pharmaceutical companies and AI providers for the implementation of AI technology designed for the complete drug development process. However, the Other segment is expected to have the fastest CAGR during the forecast period.

This growth can be attributed to the increased use of AI-based solutions by government agencies and research organizations (CROs). These solutions improve data quality, increase patient compliance and retention, and reduce clinical trial costs by making more accurate decisions. Effectiveness of treatment.

local market

In 2022, the North America region will account for the highest revenue in the AI-based clinical trial solutions market and is expected to maintain its dominance during the forecast period. This is due to the increasing number of startups using it. Additionally, there are numerous clinical studies registered in the region, benefiting the industry.

Segmentation: AI-Based Clinical Trial Solutions for Patient Matching Market Report 2022 – 2033

Therapeutic Applications (Revenue, USD million), 2022-2033

  • cardiovascular disease

  • Infection

  • metabolic disease

  • oncology

  • neurological disease

  • others

End Users (Revenue, USD Million), 2022-2033

  • academia

  • Pharmaceutical company

  • others

By Region (Revenue, USD Million), 2022-2033

North America


  • Germany

  • France

  • UK

  • Spain

  • Italy

  • rest of europe

Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Korea

  • Rest of Asia Pacific

latin america

  • Brazil

  • Mexico

  • Argentina

  • rest of latin america

Middle East and Africa

  • South Africa

  • GCC

  • Rest of the MEA

Main topics:

1. Survey method


3. Abstract

4. Market dynamics

5. Market environment analysis

6. COVID-19 Impact Analysis: AI-Based Clinical Trial Solutions for Patient Matching Market

7. Market analysis by therapeutic application

8. Market Analysis by End User

9. Regional market analysis

10. AI-Based Clinical Trial Solutions for North American Patient Matching Market

11. AI-based clinical trial solutions for the European patient matching market

12. Asia-Pacific AI-based Clinical Trial Solutions for Patient Matching Market

13. Latin America AI-based Clinical Trial Solutions for Patient Matching Market

14. MEA AI-Based Clinical Trial Solutions for Patient Matching Market

15. Competitor Analysis

16. Company Profile


companies mentioned

  • AmerisourceBergen Corporation

  • Alice Global

  • Antidote Technologies Co., Ltd.

  • deep lens

  • Unlearn.AI Inc.


  • Connected

  • microsoft


  • GNS health care.

For more information on this report, please visit

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *